[
    {
        "text": "(upbeat music)",
        "start": 0.273,
        "duration": 2.583
    },
    {
        "text": "Hi everyone, can you see me?",
        "start": 7.54,
        "duration": 2.167
    },
    {
        "text": "Yes.",
        "start": 14.001,
        "duration": 1.147
    },
    {
        "text": "Okay, great.",
        "start": 15.148,
        "duration": 1.167
    },
    {
        "text": "The cancer treatment has experienced three revolutions.",
        "start": 18.43,
        "duration": 3.98
    },
    {
        "text": "It started with more than 70 years ago,",
        "start": 22.41,
        "duration": 3.13
    },
    {
        "text": "the development of cytotoxic drugs",
        "start": 25.54,
        "duration": 2.73
    },
    {
        "text": "that work by killing the fastest growing cells.",
        "start": 28.27,
        "duration": 4.29
    },
    {
        "text": "However, this type of therapy",
        "start": 32.56,
        "duration": 1.83
    },
    {
        "text": "cannot kill the last cancer cell without killing the person",
        "start": 34.39,
        "duration": 4.09
    },
    {
        "text": "because cancer cells are not the fastest growing cells",
        "start": 38.48,
        "duration": 3.77
    },
    {
        "text": "in our body.",
        "start": 42.25,
        "duration": 0.833
    },
    {
        "text": "The second revolution was marked",
        "start": 44.3,
        "duration": 2.2
    },
    {
        "text": "by the development of target therapies",
        "start": 46.5,
        "duration": 3.29
    },
    {
        "text": "that inhibit pathways that cancer cells are addicted to.",
        "start": 49.79,
        "duration": 5.0
    },
    {
        "text": "However, cancer cells can always evolve",
        "start": 54.92,
        "duration": 3.29
    },
    {
        "text": "to be addicted to something else.",
        "start": 58.21,
        "duration": 1.65
    },
    {
        "text": "So drug resistance can averagely occur.",
        "start": 60.74,
        "duration": 3.283
    },
    {
        "text": "The third revolution is marked by the development",
        "start": 65.02,
        "duration": 3.88
    },
    {
        "text": "of immunotherapy and perhaps it's best publicized",
        "start": 68.9,
        "duration": 4.68
    },
    {
        "text": "by this example.",
        "start": 73.58,
        "duration": 2.35
    },
    {
        "text": "This is president Jimmy Carter,",
        "start": 75.93,
        "duration": 2.24
    },
    {
        "text": "who is shown here posing for his 90th birthday,",
        "start": 78.17,
        "duration": 3.99
    },
    {
        "text": "soon after he was diagnosed with stage 4 melanoma.",
        "start": 82.16,
        "duration": 4.96
    },
    {
        "text": "The cancer was discovered during a routine checkup",
        "start": 87.12,
        "duration": 2.5
    },
    {
        "text": "in his liver and in his brain.",
        "start": 90.54,
        "duration": 3.62
    },
    {
        "text": "He thought he had weeks to live.",
        "start": 94.16,
        "duration": 2.72
    },
    {
        "text": "The only thing he could do was to pray.",
        "start": 96.88,
        "duration": 3.04
    },
    {
        "text": "However, he was put on an experimental drug",
        "start": 99.92,
        "duration": 4.19
    },
    {
        "text": "being developed by Merck at the time,",
        "start": 104.11,
        "duration": 2.71
    },
    {
        "text": "called immune checkpoint",
        "start": 106.82,
        "duration": 1.63
    },
    {
        "text": "and he was miraculously cured.",
        "start": 109.3,
        "duration": 2.87
    },
    {
        "text": "He was among the 20% of very lucky few",
        "start": 112.17,
        "duration": 4.19
    },
    {
        "text": "who have melanoma.",
        "start": 116.36,
        "duration": 2.223
    },
    {
        "text": "Because of this breakthrough,",
        "start": 119.67,
        "duration": 1.83
    },
    {
        "text": "James Alison and Tasuku Honjo",
        "start": 121.5,
        "duration": 2.85
    },
    {
        "text": "shared the Nobel prize in 2018 for their discovery",
        "start": 124.35,
        "duration": 3.94
    },
    {
        "text": "of the fundamental molecular mechanism",
        "start": 128.29,
        "duration": 2.33
    },
    {
        "text": "of how cancers put on brakes on our immune cells",
        "start": 130.62,
        "duration": 4.87
    },
    {
        "text": "and also for their proof of concept development",
        "start": 135.49,
        "duration": 4.21
    },
    {
        "text": "of treatment that unleash the brakes,",
        "start": 139.7,
        "duration": 3.53
    },
    {
        "text": "they're called checkpoint blockade.",
        "start": 143.23,
        "duration": 2.093
    },
    {
        "text": "However, checkpoint blockade",
        "start": 147.57,
        "duration": 2.55
    },
    {
        "text": "does not work for breast or pancreatic cancers.",
        "start": 150.12,
        "duration": 5.0
    },
    {
        "text": "In 2017 alone, we've lost two brilliant scientists,",
        "start": 155.15,
        "duration": 5.0
    },
    {
        "text": "mentor and friend at Stanford",
        "start": 162.41,
        "duration": 3.76
    },
    {
        "text": "to breast cancer and pancreatic cancers.",
        "start": 166.17,
        "duration": 2.703
    },
    {
        "text": "I wasn't planning on sharing",
        "start": 170.36,
        "duration": 1.94
    },
    {
        "text": "this personal history of myself.",
        "start": 172.3,
        "duration": 2.91
    },
    {
        "text": "However, I was inspired by the previous speakers,",
        "start": 175.21,
        "duration": 3.83
    },
    {
        "text": "Steward and the other talented speakers.",
        "start": 179.04,
        "duration": 3.98
    },
    {
        "text": "I think that my story will inspire everyone",
        "start": 183.02,
        "duration": 5.0
    },
    {
        "text": "in the current time",
        "start": 188.3,
        "duration": 1.37
    },
    {
        "text": "where we all face uncertainty and despair.",
        "start": 189.67,
        "duration": 3.593
    },
    {
        "text": "I myself was diagnosed with breast cancer in 2012",
        "start": 194.16,
        "duration": 3.387
    },
    {
        "text": "and I decided that I will not dwell on faith",
        "start": 199.72,
        "duration": 5.0
    },
    {
        "text": "that I cannot control,",
        "start": 205.88,
        "duration": 1.91
    },
    {
        "text": "instead, I will work on things that I'm empowered to change.",
        "start": 207.79,
        "duration": 5.0
    },
    {
        "text": "So when I was being wheeled into the surgical room,",
        "start": 213.95,
        "duration": 4.25
    },
    {
        "text": "I was talking to my surgeon",
        "start": 218.2,
        "duration": 1.47
    },
    {
        "text": "about how Macoma, it's not a TR7 agonist,",
        "start": 219.67,
        "duration": 4.95
    },
    {
        "text": "it activates the inflammasome.",
        "start": 224.62,
        "duration": 1.5
    },
    {
        "text": "And when I was waiting in infusion rooms,",
        "start": 227.44,
        "duration": 3.28
    },
    {
        "text": "I was often either typing a cover letter to the editor",
        "start": 230.72,
        "duration": 3.62
    },
    {
        "text": "saying that humans thing needs to be activated",
        "start": 234.34,
        "duration": 3.67
    },
    {
        "text": "or writing on a niche grant,",
        "start": 238.01,
        "duration": 2.14
    },
    {
        "text": "which I would not hear about for another year.",
        "start": 240.15,
        "duration": 2.733
    },
    {
        "text": "I decided that the more certain I am about my own future,",
        "start": 244.03,
        "duration": 5.0
    },
    {
        "text": "the more I want to work on something big,",
        "start": 249.82,
        "duration": 2.72
    },
    {
        "text": "something that takes longer, with bigger impact.",
        "start": 252.54,
        "duration": 3.733
    },
    {
        "text": "So I decided to ask why checkpoint blockade",
        "start": 257.12,
        "duration": 4.55
    },
    {
        "text": "does not work on breast cancer and pancreatic cancers.",
        "start": 261.67,
        "duration": 4.703
    },
    {
        "text": "Now the field acknowledges that perhaps",
        "start": 267.5,
        "duration": 3.63
    },
    {
        "text": "part of the reason is that early tumors",
        "start": 271.13,
        "duration": 4.28
    },
    {
        "text": "that already have T-cells infiltrating them,",
        "start": 275.41,
        "duration": 4.54
    },
    {
        "text": "that you can use checkpoint blockade",
        "start": 279.95,
        "duration": 2.36
    },
    {
        "text": "to unleash the T-cells power to directly kill cancer cells.",
        "start": 282.31,
        "duration": 5.0
    },
    {
        "text": "However, most tumors are what we call",
        "start": 288.14,
        "duration": 3.21
    },
    {
        "text": "immunologically cold tumors.",
        "start": 291.35,
        "duration": 2.76
    },
    {
        "text": "They're simply quiet",
        "start": 294.11,
        "duration": 1.44
    },
    {
        "text": "and do not have much T-cell infiltration.",
        "start": 295.55,
        "duration": 3.87
    },
    {
        "text": "So the idea is, how everyone is trying to figure out",
        "start": 299.42,
        "duration": 4.42
    },
    {
        "text": "how we can turn cold tumors hot.",
        "start": 303.84,
        "duration": 2.333
    },
    {
        "text": "And I thought, let's activate the innate immune system",
        "start": 307.05,
        "duration": 4.93
    },
    {
        "text": "because the innate immune system is our first line",
        "start": 311.98,
        "duration": 3.08
    },
    {
        "text": "of defense against any invasion, including cancer",
        "start": 315.06,
        "duration": 4.7
    },
    {
        "text": "and it is upstream of adaptive immunity, namely T-cell.",
        "start": 319.76,
        "duration": 4.48
    },
    {
        "text": "So the specific questions we ask are,",
        "start": 326.631,
        "duration": 2.386
    },
    {
        "text": "what is the danger signal secreted by cancer cells",
        "start": 329.92,
        "duration": 3.57
    },
    {
        "text": "and that is detected by our innate immune system?",
        "start": 333.49,
        "duration": 2.933
    },
    {
        "text": "And how do cancer cells disguise themselves",
        "start": 337.46,
        "duration": 3.6
    },
    {
        "text": "from innate immune detection?",
        "start": 341.06,
        "duration": 2.417
    },
    {
        "text": "And can we blow cancers covers?",
        "start": 343.477,
        "duration": 2.096
    },
    {
        "text": "So the answer now lies in this pathway.",
        "start": 347.07,
        "duration": 2.843
    },
    {
        "text": "So a decade of intense research by many labs in the field,",
        "start": 350.98,
        "duration": 4.23
    },
    {
        "text": "we now know that cancer cells, for various reasons,",
        "start": 355.21,
        "duration": 5.0
    },
    {
        "text": "have double stranded DNA in their cytosol,",
        "start": 360.3,
        "duration": 2.763
    },
    {
        "text": "where it should not be.",
        "start": 364.23,
        "duration": 1.48
    },
    {
        "text": "Double stranded DNA should only be in the nucleus",
        "start": 365.71,
        "duration": 2.3
    },
    {
        "text": "or in mitochondria.",
        "start": 368.01,
        "duration": 1.103
    },
    {
        "text": "So when it's in the cytosol,",
        "start": 370.01,
        "duration": 1.62
    },
    {
        "text": "it's considered by augmenting your system,",
        "start": 371.63,
        "duration": 2.64
    },
    {
        "text": "a dangerous signal.",
        "start": 374.27,
        "duration": 0.993
    },
    {
        "text": "Augmenting your system then makes a second messenger",
        "start": 376.8,
        "duration": 3.05
    },
    {
        "text": "called a cyclic GMP-AMP or cGAMP for short.",
        "start": 379.85,
        "duration": 3.913
    },
    {
        "text": "The second messenger, this beautiful molecule once made,",
        "start": 385.14,
        "duration": 4.18
    },
    {
        "text": "then activates a powerful downstream",
        "start": 389.32,
        "duration": 2.88
    },
    {
        "text": "effector protein called stimulator of interferon genes",
        "start": 392.2,
        "duration": 5.0
    },
    {
        "text": "or STING for short.",
        "start": 397.29,
        "duration": 1.92
    },
    {
        "text": "STING activation then leads to production of interferon,",
        "start": 399.21,
        "duration": 3.65
    },
    {
        "text": "which itself is a potent cytokine",
        "start": 402.86,
        "duration": 3.09
    },
    {
        "text": "and also recruits downstream T-cells.",
        "start": 405.95,
        "duration": 3.033
    },
    {
        "text": "So I had a hypothesis.",
        "start": 410.42,
        "duration": 2.0
    },
    {
        "text": "If STING is a powerful anticancer pathway,",
        "start": 412.42,
        "duration": 3.39
    },
    {
        "text": "can we use cGAMP, it's naturally agent to activate STING?",
        "start": 415.81,
        "duration": 3.793
    },
    {
        "text": "The problem is all second messengers are short-lived",
        "start": 420.46,
        "duration": 3.86
    },
    {
        "text": "because they're degradation and synthesis",
        "start": 424.32,
        "duration": 4.03
    },
    {
        "text": "are tightly controlled.",
        "start": 428.35,
        "duration": 1.643
    },
    {
        "text": "So as a chemist by training,",
        "start": 431.22,
        "duration": 2.61
    },
    {
        "text": "I made the first contribution",
        "start": 433.83,
        "duration": 1.86
    },
    {
        "text": "by making this molecule stable",
        "start": 435.69,
        "duration": 2.56
    },
    {
        "text": "and this molecule became the prototype",
        "start": 439.32,
        "duration": 2.94
    },
    {
        "text": "of Novartis Merck experimental drugs",
        "start": 442.26,
        "duration": 2.96
    },
    {
        "text": "that are currently being tested in clinics.",
        "start": 445.22,
        "duration": 2.403
    },
    {
        "text": "Then I started my journey",
        "start": 449.81,
        "duration": 2.06
    },
    {
        "text": "at Stanford biochemistry and ChEM-H.",
        "start": 451.87,
        "duration": 2.94
    },
    {
        "text": "There, my lab, Sabrina and Daniel discovered",
        "start": 454.81,
        "duration": 5.0
    },
    {
        "text": "how cGAMP and its analogs activate STING.",
        "start": 460.69,
        "duration": 4.473
    },
    {
        "text": "They discovered that STING forms a polymer once activated",
        "start": 466.33,
        "duration": 5.0
    },
    {
        "text": "and this polymer is key",
        "start": 471.61,
        "duration": 2.23
    },
    {
        "text": "for its downstream adaptor protein function.",
        "start": 473.84,
        "duration": 2.933
    },
    {
        "text": "And to a chemist like me,",
        "start": 477.7,
        "duration": 1.65
    },
    {
        "text": "when I see polymer, I see a chain reaction,",
        "start": 479.35,
        "duration": 4.45
    },
    {
        "text": "I see a irreversible event.",
        "start": 483.8,
        "duration": 3.08
    },
    {
        "text": "So once STING is activated,",
        "start": 486.88,
        "duration": 1.85
    },
    {
        "text": "there's no going back.",
        "start": 488.73,
        "duration": 2.03
    },
    {
        "text": "As a result, you only want to activate STING",
        "start": 490.76,
        "duration": 3.65
    },
    {
        "text": "in the tumors.",
        "start": 494.41,
        "duration": 2.39
    },
    {
        "text": "When STING is activated at places where it should not be,",
        "start": 496.8,
        "duration": 3.78
    },
    {
        "text": "we have trouble.",
        "start": 500.58,
        "duration": 1.75
    },
    {
        "text": "STING activation in the heart",
        "start": 502.33,
        "duration": 1.98
    },
    {
        "text": "or in the skin or in the brain,",
        "start": 504.31,
        "duration": 2.233
    },
    {
        "text": "is a cause of heart attack-induced death",
        "start": 507.48,
        "duration": 3.34
    },
    {
        "text": "and inflammation in lupus, Parkinson's",
        "start": 510.82,
        "duration": 3.31
    },
    {
        "text": "and multiple sclerosis.",
        "start": 514.13,
        "duration": 1.943
    },
    {
        "text": "Systemic STING activation by a mutation",
        "start": 517.28,
        "duration": 4.87
    },
    {
        "text": "causes a hyper inflammation disease",
        "start": 522.15,
        "duration": 2.71
    },
    {
        "text": "that leads to early death in children.",
        "start": 524.86,
        "duration": 1.9
    },
    {
        "text": "As a result, STING agonists when being tested in clinics",
        "start": 528.53,
        "duration": 4.46
    },
    {
        "text": "are all directly injected into the tumors.",
        "start": 532.99,
        "duration": 3.5
    },
    {
        "text": "This limits the type of patients we can treat.",
        "start": 536.49,
        "duration": 2.533
    },
    {
        "text": "So is there another way?",
        "start": 540.86,
        "duration": 1.333
    },
    {
        "text": "A second contribution I made was to identify",
        "start": 544.0,
        "duration": 4.44
    },
    {
        "text": "the first and to this day, the only hydrolase",
        "start": 548.44,
        "duration": 3.1
    },
    {
        "text": "of cGAMP called ENPP1.",
        "start": 551.54,
        "duration": 2.513
    },
    {
        "text": "And this, not only did not solve the problem,",
        "start": 555.35,
        "duration": 3.22
    },
    {
        "text": "but started a bigger puzzle.",
        "start": 558.57,
        "duration": 2.93
    },
    {
        "text": "This is because ENPP1 is an extracellular enzyme,",
        "start": 561.5,
        "duration": 4.37
    },
    {
        "text": "while cGAMP is an intracellular second messenger.",
        "start": 565.87,
        "duration": 4.243
    },
    {
        "text": "I had a wild hypothesis and that is, cGAMP is exported out",
        "start": 571.75,
        "duration": 5.0
    },
    {
        "text": "by cells to function as an extracellular messenger.",
        "start": 578.83,
        "duration": 4.553
    },
    {
        "text": "And Stanford biochemistry in CHEM-H believed in me",
        "start": 584.47,
        "duration": 3.51
    },
    {
        "text": "and recruited me to test this hypothesis.",
        "start": 587.98,
        "duration": 3.783
    },
    {
        "text": "Jackie Carozza in my lab used",
        "start": 593.24,
        "duration": 1.83
    },
    {
        "text": "the hardcore analytical chemistry.",
        "start": 595.07,
        "duration": 2.29
    },
    {
        "text": "Using tricks that we're also familiar with,",
        "start": 597.36,
        "duration": 3.21
    },
    {
        "text": "she developed isotopically-labeled internal standards",
        "start": 600.57,
        "duration": 4.27
    },
    {
        "text": "and build cell lines as tools",
        "start": 604.84,
        "duration": 2.73
    },
    {
        "text": "to show that in perfectly intact cancer cells",
        "start": 607.57,
        "duration": 5.0
    },
    {
        "text": "where you do not see cell death,",
        "start": 612.82,
        "duration": 2.79
    },
    {
        "text": "these cells are pumping out cGAMP as a soluble molecule.",
        "start": 615.61,
        "duration": 4.513
    },
    {
        "text": "And if you remove this soluble molecule",
        "start": 621.75,
        "duration": 3.49
    },
    {
        "text": "from a tumor, radiate tumors can no longer be cured,",
        "start": 625.24,
        "duration": 5.0
    },
    {
        "text": "suggesting extracellular cGAMP",
        "start": 632.39,
        "duration": 2.59
    },
    {
        "text": "is how ionizing radiation exerts its curative effects",
        "start": 635.82,
        "duration": 5.0
    },
    {
        "text": "in this tumor model.",
        "start": 640.83,
        "duration": 1.373
    },
    {
        "text": "So now we know that cancer cells cannot help,",
        "start": 644.27,
        "duration": 3.87
    },
    {
        "text": "but constantly make cGAMP due to their cytosol DNA",
        "start": 648.14,
        "duration": 4.54
    },
    {
        "text": "and then they constantly pump out cGAMP",
        "start": 652.68,
        "duration": 2.8
    },
    {
        "text": "to the tumor microenvironment.",
        "start": 655.48,
        "duration": 2.35
    },
    {
        "text": "We asked, how does a host recognize extracellular cGAMP?",
        "start": 657.83,
        "duration": 4.383
    },
    {
        "text": "Now, Sir Anthony and Volker's work.",
        "start": 663.2,
        "duration": 3.01
    },
    {
        "text": "We know that many innate new cells",
        "start": 666.21,
        "duration": 3.1
    },
    {
        "text": "are the first responders,",
        "start": 669.31,
        "duration": 1.82
    },
    {
        "text": "including macrophages and monocytes.",
        "start": 671.13,
        "duration": 3.63
    },
    {
        "text": "They take up cGAMP, non-producing interferon",
        "start": 674.76,
        "duration": 3.59
    },
    {
        "text": "to recruit the downstream P-cells",
        "start": 678.35,
        "duration": 2.74
    },
    {
        "text": "into the tumor microenvironment",
        "start": 681.09,
        "duration": 2.12
    },
    {
        "text": "and that's how you turn cold tumors hot.",
        "start": 683.21,
        "duration": 2.673
    },
    {
        "text": "My lab then collectively identified",
        "start": 687.92,
        "duration": 2.22
    },
    {
        "text": "the first three transporters",
        "start": 690.14,
        "duration": 2.4
    },
    {
        "text": "these first responders use",
        "start": 692.54,
        "duration": 1.94
    },
    {
        "text": "to take up cGAMP, ranging from a known transporter",
        "start": 694.48,
        "duration": 4.36
    },
    {
        "text": "to orphan transporter, to ion channels.",
        "start": 699.94,
        "duration": 3.743
    },
    {
        "text": "So now starting from a picture that the field build,",
        "start": 704.94,
        "duration": 4.51
    },
    {
        "text": "and starting from a hint to that",
        "start": 709.45,
        "duration": 2.42
    },
    {
        "text": "as a double negatively-charged molecule,",
        "start": 711.87,
        "duration": 2.43
    },
    {
        "text": "cGAMP can cross the cell membrane.",
        "start": 714.3,
        "duration": 2.56
    },
    {
        "text": "I build the first now hydrolyzable cGAMP analog",
        "start": 716.86,
        "duration": 4.31
    },
    {
        "text": "and my lab understood that it activates STING",
        "start": 721.17,
        "duration": 3.44
    },
    {
        "text": "by triggering polymerization.",
        "start": 724.61,
        "duration": 1.733
    },
    {
        "text": "I identified the first hydrolase of cGAMP,",
        "start": 727.31,
        "duration": 4.25
    },
    {
        "text": "which turns out to be an extracellular enzyme",
        "start": 731.56,
        "duration": 2.89
    },
    {
        "text": "and that started the observation",
        "start": 734.45,
        "duration": 2.15
    },
    {
        "text": "that cancer cells use various exporters",
        "start": 736.6,
        "duration": 3.24
    },
    {
        "text": "to pump out cGAMP, to get rid of it.",
        "start": 739.84,
        "duration": 3.75
    },
    {
        "text": "And then whole cells use cell-type specific transporters",
        "start": 743.59,
        "duration": 5.0
    },
    {
        "text": "to take in to fight cancer.",
        "start": 749.13,
        "duration": 2.123
    },
    {
        "text": "So now this started the paradigm that cGAMP",
        "start": 752.14,
        "duration": 3.28
    },
    {
        "text": "is an immuno-transmitter and it's very locally-produced",
        "start": 755.42,
        "duration": 4.04
    },
    {
        "text": "by cancer cells in the tumor micro-environment.",
        "start": 759.46,
        "duration": 3.44
    },
    {
        "text": "So that is a standard signal,",
        "start": 762.9,
        "duration": 3.18
    },
    {
        "text": "cold tumor sent out to the host",
        "start": 766.08,
        "duration": 3.97
    },
    {
        "text": "to be detected, except they're smart.",
        "start": 770.05,
        "duration": 2.88
    },
    {
        "text": "So some tumors over-express ENPP1",
        "start": 772.93,
        "duration": 4.67
    },
    {
        "text": "to chew up the standard signal.",
        "start": 777.6,
        "duration": 2.13
    },
    {
        "text": "This is how they disguise.",
        "start": 779.73,
        "duration": 2.22
    },
    {
        "text": "So we blow their covers by developing ENPP1 inhibitors,",
        "start": 781.95,
        "duration": 5.0
    },
    {
        "text": "which now can treat notoriously cold breast",
        "start": 787.49,
        "duration": 4.48
    },
    {
        "text": "and pancreatic cancers in mice.",
        "start": 791.97,
        "duration": 2.703
    },
    {
        "text": "So now with this, and there was many labs",
        "start": 795.53,
        "duration": 2.74
    },
    {
        "text": "who are working on the forefront of innate immune signaling,",
        "start": 798.27,
        "duration": 3.74
    },
    {
        "text": "we're leading the force revolution",
        "start": 802.01,
        "duration": 3.1
    },
    {
        "text": "in cancer treatment, thank you.",
        "start": 805.11,
        "duration": 2.423
    },
    {
        "text": "Thank you so much Lingyin there.",
        "start": 815.61,
        "duration": 1.417
    },
    {
        "text": "Has that moved over to me?",
        "start": 817.027,
        "duration": 2.006
    },
    {
        "text": "Oh, it is, okay, there we go, thank you.",
        "start": 820.39,
        "duration": 1.96
    },
    {
        "text": "I think I'm getting a little bit of a delay, my apologies.",
        "start": 822.35,
        "duration": 2.28
    },
    {
        "text": "Thank you so much for that great talk Lingyin.",
        "start": 824.63,
        "duration": 2.65
    },
    {
        "text": "I learned so much and I appreciate your personal story,",
        "start": 827.28,
        "duration": 4.25
    },
    {
        "text": "thank you for sharing that with us.",
        "start": 831.53,
        "duration": 2.76
    },
    {
        "text": "I wanted to ask, you've identified ENPP1",
        "start": 834.29,
        "duration": 3.68
    },
    {
        "text": "as this potential drug target.",
        "start": 839.21,
        "duration": 2.2
    },
    {
        "text": "Obviously STING has become this really hot area",
        "start": 841.41,
        "duration": 3.17
    },
    {
        "text": "of drug discovery,",
        "start": 844.58,
        "duration": 1.11
    },
    {
        "text": "You talked about how one of the compounds you made",
        "start": 845.69,
        "duration": 2.71
    },
    {
        "text": "was the inspiration for things that are now in the clinic.",
        "start": 849.47,
        "duration": 3.17
    },
    {
        "text": "Are you yourself entrepreneurial?",
        "start": 852.64,
        "duration": 1.65
    },
    {
        "text": "I mean, do you think that you'll at some point",
        "start": 854.29,
        "duration": 2.01
    },
    {
        "text": "start a company around that target or something else?",
        "start": 856.3,
        "duration": 3.553
    },
    {
        "text": "Lisa, thank you for the question.",
        "start": 862.51,
        "duration": 2.44
    },
    {
        "text": "We have spun out a company that are now developing",
        "start": 864.95,
        "duration": 4.95
    },
    {
        "text": "ENPP1 inhibitors and right now is in preclinical stage.",
        "start": 869.9,
        "duration": 4.51
    },
    {
        "text": "This will be the first of many companies",
        "start": 874.41,
        "duration": 2.87
    },
    {
        "text": "that I probably will start",
        "start": 877.28,
        "duration": 2.83
    },
    {
        "text": "because I do realize that to translate",
        "start": 880.11,
        "duration": 3.82
    },
    {
        "text": "from benchside to bedside,",
        "start": 883.93,
        "duration": 2.03
    },
    {
        "text": "we do need much larger resources that academics can have.",
        "start": 885.96,
        "duration": 5.0
    },
    {
        "text": "So I wanted to ask you,",
        "start": 893.01,
        "duration": 1.52
    },
    {
        "text": "you kind of started from this point,",
        "start": 894.53,
        "duration": 2.07
    },
    {
        "text": "I think in your postdoc, that kind of unraveled",
        "start": 896.6,
        "duration": 3.06
    },
    {
        "text": "into your lab and you keep finding new questions",
        "start": 899.66,
        "duration": 3.21
    },
    {
        "text": "that really open up big new areas of science.",
        "start": 902.87,
        "duration": 2.99
    },
    {
        "text": "Do you think you're gonna stay",
        "start": 905.86,
        "duration": 1.49
    },
    {
        "text": "in this kind of immuno-oncology space?",
        "start": 907.35,
        "duration": 3.28
    },
    {
        "text": "There's certainly no shortage of questions,",
        "start": 910.63,
        "duration": 1.65
    },
    {
        "text": "but what's next after ENPP1?",
        "start": 912.28,
        "duration": 2.883
    },
    {
        "text": "That's a great question",
        "start": 918.21,
        "duration": 1.67
    },
    {
        "text": "and it's a hard question to answer now.",
        "start": 919.88,
        "duration": 3.783
    },
    {
        "text": "To be honest, I am torn between two models.",
        "start": 925.27,
        "duration": 4.8
    },
    {
        "text": "As a chemist, my projects had changed more often than now",
        "start": 930.07,
        "duration": 5.0
    },
    {
        "text": "and now when we're working on immunotherapy,",
        "start": 937.24,
        "duration": 2.26
    },
    {
        "text": "we realize that it really takes decades of research.",
        "start": 939.5,
        "duration": 3.68
    },
    {
        "text": "You not only have to identify the molecular mechanisms,",
        "start": 943.18,
        "duration": 3.86
    },
    {
        "text": "but also have to develop the prototypes of therapeutics",
        "start": 947.04,
        "duration": 4.37
    },
    {
        "text": "as proof of concept,",
        "start": 953.077,
        "duration": 0.933
    },
    {
        "text": "otherwise no one would believe you for that case.",
        "start": 954.01,
        "duration": 2.453
    },
    {
        "text": "Yeah, well really, again,",
        "start": 957.44,
        "duration": 3.49
    },
    {
        "text": "I've seen a lot of comments on here",
        "start": 960.93,
        "duration": 1.42
    },
    {
        "text": "that are more comments about how much",
        "start": 962.35,
        "duration": 1.46
    },
    {
        "text": "everyone enjoyed your talk.",
        "start": 963.81,
        "duration": 1.42
    },
    {
        "text": "So thank you so much Lingyin,",
        "start": 965.23,
        "duration": 2.08
    },
    {
        "text": "we were so pleased that we got to learn",
        "start": 967.31,
        "duration": 1.96
    },
    {
        "text": "about your research today, thank you.",
        "start": 969.27,
        "duration": 2.326
    },
    {
        "text": "(upbeat music)",
        "start": 971.596,
        "duration": 2.583
    }
]